CJC-1295 DAC

CJC-1295 DAC is a modified analog of growth hormone releasing hormone (GHRH), a naturally occurring peptide in the brain that stimulates the pituitary gland to produce and release growth hormone. The "DAC" (Drug Affinity Complex) refers to a lysine-based addition that extends the half-life of the peptide from minutes to approximately 6-8 days, allowing once or twice-weekly administration instead of multiple daily injections.

CJC-1295 DAC was developed to improve upon unmodified GHRH, which has an extremely short half-life of just 7 minutes due to rapid degradation by dipeptidyl peptidase IV (DPP-IV) in the bloodstream. The DAC modification protects CJC-1295 from this enzymatic degradation, creating a long-acting GHRH analog suitable for research and personal use protocols.

The peptide has become one of the most popular GH secretagogues in research communities due to its long-acting nature, making it more practical than short-acting peptides like GHRH or GHRP variants.

GHRH receptor activation: CJC-1295 DAC binds to and activates GHRH receptors on somatotroph cells in the anterior pituitary gland, directly stimulating growth hormone synthesis and secretion.

Natural pathway activation: Unlike exogenous GH injection, CJC-1295 DAC works through the body's natural GH regulation pathways, stimulating the pituitary to produce its own GH, maintaining physiological pulsatility.

Synergy with GHRP: CJC-1295 DAC is frequently combined with GHRP peptides (like GHRP-6 or GHRP-2), which work through different mechanisms (acting on ghrelin receptors rather than GHRH receptors). This combination creates synergistic GH elevation through complementary pathways.

Extended duration: The DAC modification provides 6-8 day half-life, allowing accumulation with repeated dosing and sustained GH elevation with just once or twice-weekly administration, unlike unmodified GHRH which requires 3-4 times daily dosing.

GH elevation: Clinical studies have documented 2-4x elevations in basal GH levels with CJC-1295 DAC administration. Peak GH elevations occur 2-4 hours post-injection, with elevated levels persisting for extended periods due to the long half-life.

IGF-1 elevation: As endogenous GH production increases, circulating IGF-1 levels increase in parallel, reaching plateau after 2-3 weeks of consistent CJC-1295 DAC dosing.

Body composition effects: Animal studies and limited human data suggest CJC-1295 DAC supports lean mass gain and fat loss when combined with proper training and nutrition, consistent with GH's anabolic properties.

Safety in trials: Clinical studies of CJC-1295 have shown generally favorable safety profiles with no major toxicity identified at research doses. Hypercholesterolemia and hyperglycemia have been observed as dose-dependent effects in some studies.

Important limitation: Most extensive data comes from animal studies or short-term human trials. Long-term safety and efficacy data specifically in non-GH-deficient healthy adults remain limited.

• Stimulated GH production — 2-4x elevations in endogenous growth hormone
• Muscle growth support — elevated GH and IGF-1 support muscle protein synthesis
• Fat loss promotion — GH's lipolytic effects support body recomposition
• Improved recovery — enhanced healing from training-induced muscle damage
• Convenient dosing — long half-life allows once or twice-weekly administration
• Skin health — GH supports collagen synthesis and skin quality
• Bone density improvement — GH supports bone formation and mineral density
• Anti-aging potential — age-related GH decline may be partially reversible with elevation

Standard research dosing: CJC-1295 DAC is typically administered at 2-3 mg per injection, with injections given once or twice weekly depending on protocol and preference.

Dosing schedules: Common protocols include 2-3 mg weekly as a single dose, or 2 mg twice weekly (Monday and Thursday, for example). Some protocols use 3 mg once weekly.

Combined protocols: CJC-1295 DAC is frequently combined with GHRP peptides (GHRP-6 or GHRP-2) at 50-100 mcg doses, administered 1-3 times daily on non-CJC days or concurrently with CJC injections for additive GH stimulation.

Cycle length: Research protocols typically run 8-16 weeks, with some protocols including rest periods (e.g., 12 weeks on, 4 weeks off) to monitor whether endogenous GH suppression occurs.

Reconstitution: CJC-1295 DAC comes as lyophilized powder requiring reconstitution with bacteriostatic water, typically 2-3 mL per 2-3 mg vial.

Common side effects: Injection site reactions (redness, swelling, mild pain), mild water retention, transient flushing or headache with injections, and potential carpal tunnel syndrome or joint aches in some users.

Metabolic effects: Elevated glucose and insulin levels have been observed in some studies, particularly at higher doses, relevant for individuals at risk for or with diagnosed diabetes.

Potential concerns: Theoretical risk of pituitary overstimulation with long-term use at high doses remains unclear. Natural endogenous GH production suppression during use is possible but generally considered reversible with cessation.

Safety considerations: Individuals with untreated sleep apnea, pituitary disorders, or at risk for diabetes should approach CJC-1295 DAC cautiously. Users should be aware that long-term effects in non-GH-deficient populations remain understudied.